Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Eager For More Master Protocols in Oncology: Approach Means Lower Cost For Sponsors—and Less Control

This article was originally published in RPM Report

Executive Summary

FDA officials are enthusiastic about broad, multi-agent cancer trials built on the I-SPY model. For sponsors, the trials mean less control over the development path and ultimate value proposition for the therapy—but may have important benefits on defending high prices for truly effective new therapies.

You may also be interested in...



Ebola Outbreak Draws Investor Attention; Real Impact May Be Clinical Trial Models

The race is on to develop Ebola treatments and vaccines. Investors have noticed. But the biggest impact on drug development from the Ebola outbreak may be innovation in clinical trial models – not therapeutics.

Hill Hearing Casts Spotlight On FDA Drug Approval Process

FDA’s Janet Woodcock defends the agency against criticism its review process is too slow; Congressman says FDA should proceed with antibiotic development program without waiting for new statutory authority.

Lung Cancer “Master Protocol” Eyed As Paradigm-Changing Approach To Drug Development

The biomarker-driven, multi-arm, multi-drug registration trial is expected to get under way in March 2014 with five drugs from different sponsors. With the promise of greater speed and efficiency in patient enrollment and late-stage development, it is being viewed as a potential model for other cancer settings.

Related Content

Topics

UsernamePublicRestriction

Register

PS081047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel